<DOC>
	<DOCNO>NCT02158767</DOCNO>
	<brief_summary>This clinical trial study use second infusion donor hematopoietic cell removal T cell treatment engraftment failure first hematopoietic stem cell transplant . Hematopoietic cell transplant donor complicate complete incomplete failure recovery blood count . This result frequent needs transfusion method maintain blood count acceptable level . One way improve blood count recipient give `` booster '' dose cell donor , associate increase risk immune reaction donor cell recipient cell . To decrease risk , possible decrease amount T cell , responsible type immune reaction . These cell remove special handling graft , allow remove cell directly indirectly ( select cell `` stay '' graft '' ) .</brief_summary>
	<brief_title>Access Protocol . Infusion CD34+ Enriched , T Cell Depleted Hematopoietic Stem Cell Grafts .</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To provide patient suboptimal engraftment allogeneic stem cell transplantation access donor - derive , cluster differentiation ( CD34 ) + enrich T-cell depleted peripheral blood stem cell isolate CliniMACS System . OUTLINE : Patients undergo CD34+ enrich T-cell deplete peripheral blood stem cell infusion ( PBSCT ) 1-3 hour . After completion study treatment , patient follow 100 day .</detailed_description>
	<criteria>Patients receive prior hematopoietic progenitor cell transplantation , include match sibling unrelated donor transplant , mismatch sibling unrelated donor transplant haploidentical transplant related donor Patients presence secondary engraftment failure define decrease donor chimerism â‰¥ 50 % ( i.e . 40 % 20 % ) two measurement do least 30 day apart OR presence incomplete graft function manifest presence persistent new cytopenia 60 day transplantation : Anemia ; hemoglobin less 8g/dL , red blood cell transfusion requirement precede 4 week Neutropenia , absolute neutrophil count le 1,000 neutrophil per microliter requirement growth factor support precede 4 week Thrombocytopenia , platelet count 20,000 platelet per microliter platelet transfusion requirement precede 4 week Patients hematopoietic progenitor cell original donor available Presence reversible cause engraftment failure incomplete graft function , include Active viral infection Medications Acute chronic graft versus host disease ( GVHD ) control less equal stage II immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>